The Food and Drug Administration held a public hearing on September 14 on how psychedelic drugs might someday be used as supervised treatments, and the public has until October 5 to weigh in. Electronic comments must be submitted to the agency's Federal Register docket by 11:59 p.m. Eastern Time that day.
At the session, held in person at the FDA's White Oak campus in Silver Spring, Maryland, and online, doctors, veterans, pharmacists, and therapists urged regulators to set clear safety and access standards for psychedelic-assisted therapy, Reuters reported. Experts said any approved treatment must include trained staff in the room during sessions, along with proper screening, follow-up care, and community support.
For people living with depression or post-traumatic stress disorder (PTSD), and the families helping them find care, the hearing offered an early look at what treatment might involve. It was not a sign that any psychedelic drug is available now. The FDA framed the entire proceeding around potential future use.
Four Questions the Agency Put on the Table
The FDA's hearing page says the agency held the session with federal partners to gather views on psychedelic drug products used in supervised and supportive settings. The formal notice lists four topics: provider training and credentialing, patient safety, access, and data collection.
The questions are practical. The agency asked about minimum staffing during dosing sessions, the roles of licensed counselors and peer support specialists, and what informed consent should cover. Its examples included the potential for an amplified power imbalance between patient and provider, the use of therapeutic touch, and the risk of psychological distress or a challenging psychedelic experience.
It also asked how clinics should screen out people at higher risk because of conditions such as cardiovascular disease, psychosis, or suicidality, and how to prevent diversion and nonmedical use once a drug is approved. On access, the FDA sought input on insurance coverage, payment models, clinic space and capacity, secure storage, and telehealth for screening and follow-up. On data, it asked how registries, health records, insurance claims, and state psychedelic programs could help track safety in everyday use.
The agency also spelled out what it is not seeking. Comments on the safety or effectiveness of any specific drug, controlled-substance scheduling, legalization or decriminalization, religious or personal use, and complaints about specific practitioners fall outside this proceeding.
Voices from the Hearing Room
The American Psychiatric Association said it "appreciates the FDA's public hearing and coordination with federal partners on the potential therapeutic use of psychedelics," but it drew a firm line: "The FDA's determination of safety and effectiveness... must remain the foundation for any future clinical use," the group said, according to Reuters.
Robert Barrow, CEO of Definium Therapeutics, which is developing an LSD-based therapy, told Reuters the hearing offered "a nice opportunity for that continuing public dialogue." His company is among those that could benefit from a clearer regulatory path.
The FDA set ground rules for who spoke. People requesting time had to disclose any financial ties to companies developing psychedelic products or services, and commercial or promotional material was barred. Because requests were expected to exceed the time available, the agency said it would choose presenters to reflect a broad range of views.
Days before the hearing, senior FDA officials, including Michael Davis, head of the Center for Drug Evaluation and Research, published a paper in the New England Journal of Medicine outlining a framework for developing and approving psychedelic drugs, Reuters reported. Researchers noted that approved treatments are still likely years away.
A Hearing Is Not an Approval
The hearing follows a fast federal push. Executive Order 14401, signed April 18, set a policy of speeding research and appropriate approvals of psychedelic drugs for serious mental illness. Days later, the FDA issued national priority vouchers to programs studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD. The order also directed the FDA to work with the Drug Enforcement Administration on a pathway for some seriously ill patients to seek investigational treatments, Reuters reported.
The agency has also finalized guidance on clinical studies of psychedelic drugs, according to law firm Mintz. The guidance addresses functional unblinding (when a drug's noticeable effects reveal to participants which treatment they received), abuse potential, long-term follow-up, and safety monitoring.
The FDA's own notice is clear about the limits of those steps. Neither a priority voucher nor a Breakthrough Therapy designation is an FDA finding of safety or effectiveness, and neither replaces marketing approval.
That distinction matters for patients. The agency's questions about screening for psychosis and suicidality, and about the risk of psychological distress, show why supervision sits at the center of this debate. Anyone considering unregulated products or retreats should talk with a clinician first. People in crisis can call or text 988.
Filing a Comment Before the Deadline
Anyone can participate. Electronic comments go to docket FDA-2026-N-7542 on Regulations.gov, where the Federal Register listing showed 85 comments received as of September 14. Paper comments can be mailed to the FDA's Dockets Management Staff in Rockville, Maryland, and must be received by October 5.
The FDA says it considers timely written comments equally with oral presentations, so people who did not speak at the hearing are not at a disadvantage. Electronic comments are posted publicly without changes, including any names or identifying details in the comment text, so commenters should leave out medical information and anything else they want kept private. The notice explains a separate paper process for people who need to submit confidential information.
Patients and caregivers can describe barriers they expect, such as travel to a supervised clinic, time away from work, or insurance hurdles. Clinicians can speak to staffing, training, and emergency backup.
A transcript of the hearing will be posted to the docket. The agency has not said when it will act on the input. Readers should watch for the transcript, any draft policy that follows, and pending drug applications that will put these questions to a real test.
Key Questions Answered
What happened at the FDA hearing? The FDA held a public hearing on September 14 on the potential future use of psychedelic drugs in supervised settings. Doctors, veterans, pharmacists, and therapists urged clear safety and access standards.
Did the FDA approve a psychedelic treatment? No. The hearing gathered public input only. The FDA says priority vouchers and Breakthrough Therapy designations are not findings of safety or effectiveness.
What is the comment deadline? Electronic comments must be submitted to docket FDA-2026-N-7542 by 11:59 p.m. Eastern Time on October 5, 2026. Paper comments must be received by that date.
What topics does the FDA want input on? Provider training and credentialing, patient safety, access and coverage, and data collection for tracking safety.
What topics are excluded? The safety or effectiveness of specific drugs, drug scheduling, legalization or decriminalization, religious or personal use, and complaints about specific practitioners.
Will my comment be public? Yes. Electronic comments are posted as submitted, so leave out private medical details and personal identifiers you do not want shared.
Where can someone in a mental health crisis get help now? Call or text 988, or contact a licensed clinician. This article is general information and is not medical advice.
